Applying Bioinformatic Tools for Modeling and Modifying Type II E. coli l-Asparginase to Present a Better Therapeutic Agent/Drug for Acute Lymphoblastic Leukemia.
Background: Asparginase is known to be one of the most important bedrocks of acute lymphoblastic leukemia (ALL) treatment in almost all pediatric regimens in treatment protocols. Escherichia coli L-Asparginase (EC 3.5.1.1) is one of the most common resources to produce this enzyme. One of the afford...
| Published in: | International Journal of Cancer Management Vol. 10; no. 3; pp. 1 - 11 |
|---|---|
| Main Authors: | , , , , , |
| Format: | pictorial research tables/charts Journal Article |
| Published: |
Medical Journals Commission of the Ministry of Health & Medical Education
Mar2017
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124772319&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 124772319 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 25384422 L6AI jtl: International Journal of Cancer Management issn: 25384422 maglogo: N pubinfo: dt: Mar2017 vid: 10 iid: 3 pid: 66482 pub: Medical Journals Commission of the Ministry of Health & Medical Education artinfo: ui: 124772319 124772319 124772319 10.5812/ijcm.5785 124772319 ppf: 1 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Applying Bioinformatic Tools for Modeling and Modifying Type II E. coli l-Asparginase to Present a Better Therapeutic Agent/Drug for Acute Lymphoblastic Leukemia. aug: au: Mahboobi, Mahdieh Sedighian, Hamid Hedayati C. H., Mojtaba Bambai, Bijan Soofian, Saeed Esmaeil Amani, Jafar affil: Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran sug: subj: Bioinformatics Leukemia, Lymphocytic, Acute Therapy Asparaginase Therapeutic Use Antineoplastic Agents Therapeutic Use Escherichia Coli Computer-Aided Design Asparaginase Analogs and Derivatives Molecular Structure Evaluation Toxicity Tests Software Drug Stability Sequence Analysis Mutation Antigens Allergens Lymphoma, B-Cell Proteins ab: Background: Asparginase is known to be one of the most important bedrocks of acute lymphoblastic leukemia (ALL) treatment in almost all pediatric regimens in treatment protocols. Escherichia coli L-Asparginase (EC 3.5.1.1) is one of the most common resources to produce this enzyme. One of the affordable methods to overcome the side effects of drug is utilizing bioinformatic tools in the form of In silico study. In this study we designed a new structure of L-Asparginase to decrease its toxicity, reduce some side effects and increase the stability. Methods:We usedsomebioinformatics software and servers like Toxin red, Popmusic, kobami and I-TASSER server to reduce toxicity level of enzyme, and to increase stability and enzyme half-life. Results:We obtained 6 protein sequences in which the best was Mut 6 with four changes in structure: L23G, K129L, S263C and R291F. In contrast to the wild type, the new predicted protein is not toxic and has 25 hours more half-life and 600 kcal/mol more stable with no significant change in protein secondary, tertiary structure, antigenicity and allergenicity. Conclusions: Finally, sequence number 6 was the only sequence with all distinct characteristics: non-toxic, more stability and more half life. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|